Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
The invention relates to a novel use of known benzazepine, benzoxazepine, benzo-thiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of neurodegenerative disorders. The compounds of the invention are known from the European patents EP 0 733 642 and EP 0 916 679, and can be described by the general formulae (1): wherein the symbols have the meanings as given above in the description.
1. A method of reducing neural loss in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutical composition comprising at least one compound of the general formula (1):
wherein:
R 1 is a group with formula (2) or (3):
A is CH 2 , O or S;
R 2 and R 3 independently are hydrogen or halogen;
R 4 and R 6 independently are hydrogen or a biolabile carboxylic ester forming group;
R 5 is selected from (C 1 –C 6 )alkoxy(C 1 –C 6 )alkyl which may be substituted by a (C 1 –C 6 )alkoxy, phenyl-(C 1 –C 6 )-alkyl and phenyloxy-(C 1 –C 6 )-alkyl wherein the phenylgroup may be substituted with (C 1 –C 6 )alkyl, (C 1 –C 6 )-alkoxy or halogen, and naphtyl-(C 1 –C 6 )-alkyl; and
R 7 and R 8 independently are hydrogen or a group forming a biolabile phosphonic acid ester;
or a stereoisomer, pharmacologically acceptable salt, or prodrugs thereof.
2. The method of claim 1 , wherein the at least one compound of the general formula (1) is a compound of the general formula (4):
3. The method of claim 1 , wherein the at least one compound of the general formula (1) is a compound of the general formula (5):
4. The method of claim 1 , wherein the at least one compound of the general formula (1) is (2R)-2-{[1-({[(3S)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl] amino}carbonyl)cyclopentyl] methyl}-4-phenylbutanoic acid having formula (6):
5. The method of claim 1 , wherein the at least one compound of the general formula (1) is (2R)-2-{[1-({[(3S)-1-(carboxymethyl )-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl] methyl}-4-(1-naphthyl )butanoic acid, having formula (7):
6. The method of claim 1 , wherein the at least one compound of the general formula (1) is tert-butyl-((3S)-3-{[(1-{[(benzyloxy)(ethoxy)phosphoryl]methyl}cyclopentyl) carbonyl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetate, having formula (8):
7. The method of claim 1 , wherein the pharmacologically acceptable salt is a lithium salt, calcium salt, magnesium salt or zinc salt.
8. The method of claim 1 , wherein the neural loss is associated with one or more of traumatic brain injury, acute disseminated encephalo-myelitis, epilepsy related brain damage, spinal cord injury, bacterial or viral meningitis and meningo-encephalitis, prion diseases, poisonings with neurotoxic compounds, radiation-induced brain damage, and ischemic stroke.
9. The method of claim 8 , wherein neural loss associated with at least one of traumatic brain injury and spinal cord injury is reduced.
10. The method of claim 8 , wherein neural loss associated with at least one of acute disseminated encephalo-myelitis, epilepsy related brain damage, bacterial or viral meningitis and meningoencephalitis, prion diseases, poisonings with neurotoxic compounds, and radiation-induced brain damage is reduced.
11. The method of claim 8 , wherein neural loss associated with ischemic stroke is reduced.